What is Kadmon Holdings Profitability Rank?
Kadmon Holdings has the Profitability Rank of 0.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Kadmon Holdings's Operating Margin % for the quarter that ended in Sep. 2021 was -179.42%. As of today, Kadmon Holdings's Piotroski F-Score is 4.
Competitive Comparison of Kadmon Holdings's Profitability Rank
For the Biotechnology subindustry, Kadmon Holdings's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kadmon Holdings's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kadmon Holdings's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Kadmon Holdings's Profitability Rank falls into.
Kadmon Holdings Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Kadmon Holdings has the Profitability Rank of 0.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Kadmon Holdings's Operating Margin % for the quarter that ended in Sep. 2021 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Kadmon Holdings has an F-score of 4 indicating the company's financial situation is typical for a stable company.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
Warning Sign:
Kadmon Holdings Inc operating margin has been in 5-year decline. The average rate of decline per year is -46.7%.
4. Consistency of the profitability
5. Predictability Rank
Kadmon Holdings (Kadmon Holdings) Business Description
Traded in Other Exchanges
N/A
Address
450 East 29th Street, New York, NY, USA, 10016
Kadmon Holdings Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of small molecules and biologics with a focus on inflammatory and fibrotic diseases. Its pipeline products include Belumosudil (KD025) and KD033.
Executives
| Harlan Waksal |
director, officer: President, CEO |
WAKSAL CONSULTING LLC, 7 NORTH WILLOW STREET, SUITE 6, MONTCLAIR NJ 07042 |
| Nancy Miller-rich |
director |
C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001 |
| Cynthia Schwalm |
director |
C/O G1 THERAPEUTICS, 700 PARK OFFICES DR, SUITE 200, P.O. BOX 110341, RESEARCH TRIANGLE PARK NC 27709 |
| Arthur S Kirsch |
director |
7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4 |
| David E Cohen |
director |
3160 PORTER DRIVE, PALO ALTO CA 94304 |
| Eugene Bauer |
director |
C/O KADMON HOLDINGS, LLC 450 E 29TH STREET NEW YORK NY 10016 |
| Tasos Konidaris |
director |
103 JFK PARKWAY, SHORT HILLS NJ 07078 |
| John L Ryan |
officer: Executive Vice President, CMO |
C/O KADMON HOLDINGS, LLC, 450 E. 29TH STREET, NEW YORK NY 10016 |
| Steven Meehan |
officer: EVP, Chief Financial Officer |
450 E. 29TH STREET NEW YORK NY 10016 |
| Kyle Carver |
officer: Principal Accounting Officer, Controller |
450 EAST 29TH STREET NEW YORK NY 10016 |
| Gregory S. Moss |
officer: EVP, General Counsel, Chief Compliance Officer |
450 EAST 29TH STREET, 16TH FLOOR, NEW YORK NY 10016 |
| Perceptive Life Sciences Master Fund Ltd |
10 percent owner |
C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Perceptive Advisors Llc |
other: Former 10% owner |
51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Joseph Edelman |
10 percent owner |
C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
| Steven N. Gordon |
officer: Exec VP, GC, Chief Admin, Comp |
C/O KADMON HOLDINGS, LLC 450 E 29TH STREET NEW YORK NY 10016 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KDMN has been successfully added to your